Abstract
Schizophrenia is a complex psychiatric disorder characterised by positive and negative symptoms, cognitive impairments, attentional problems, anxiety and depressive symptoms. The use of atypical antipsychotics has generally improved clinical outcome yet medical need remains. The potential use of 5-HT1A receptor agonism is emerging as one potential area that could be exploited to improve clinical management of the disease. 5-HT1A receptor agonism will not reduce hyperprolactinaemia but does appear to enhance effects on positive, negative and cognitive symptoms and also treat attentional, depressive and anxiety symptoms whilst reducing the extrapyramidal side effect profile, compared to classical antipsychotic agents. Agonism at the 5-HT1A receptor might therefore offer potential benefits to the pallet of existing strategies for the treatment of schizophrenia. We review existing data in support of this. However, further clinical data are needed to prove these hypotheses.
Keywords: Schizophrenia, serotonin, 5-HT1A, antipsychotic, D2
Current Pharmaceutical Design
Title: Antipsychotic Medication: The Potential Role of 5-HT1A Receptor Agonism
Volume: 16 Issue: 5
Author(s): Andrew C. McCreary and Caitlin A. Jones
Affiliation:
Keywords: Schizophrenia, serotonin, 5-HT1A, antipsychotic, D2
Abstract: Schizophrenia is a complex psychiatric disorder characterised by positive and negative symptoms, cognitive impairments, attentional problems, anxiety and depressive symptoms. The use of atypical antipsychotics has generally improved clinical outcome yet medical need remains. The potential use of 5-HT1A receptor agonism is emerging as one potential area that could be exploited to improve clinical management of the disease. 5-HT1A receptor agonism will not reduce hyperprolactinaemia but does appear to enhance effects on positive, negative and cognitive symptoms and also treat attentional, depressive and anxiety symptoms whilst reducing the extrapyramidal side effect profile, compared to classical antipsychotic agents. Agonism at the 5-HT1A receptor might therefore offer potential benefits to the pallet of existing strategies for the treatment of schizophrenia. We review existing data in support of this. However, further clinical data are needed to prove these hypotheses.
Export Options
About this article
Cite this article as:
McCreary C. Andrew and Jones A. Caitlin, Antipsychotic Medication: The Potential Role of 5-HT1A Receptor Agonism, Current Pharmaceutical Design 2010; 16 (5) . https://dx.doi.org/10.2174/138161210790361470
DOI https://dx.doi.org/10.2174/138161210790361470 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetic and Pharmacogenomic Research in Psychiatry: Current Advances and Clinical Applications
Current Pharmacogenomics Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Current Drug Safety Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide
Current Protein & Peptide Science Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Current Drug Targets Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Current Psychopharmacology Review of Recent Patents on Detection and Quantification of Tremor
Recent Patents on Biomedical Engineering (Discontinued) Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Gene-Gene Interactions in a Context of Individual Variability in Antipsychotic Drug Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Machine Learning, Molecular Modeling, and QSAR Studies on Natural Products Against Alzheimer’s Disease
Current Medicinal Chemistry Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Letters in Drug Design & Discovery Involvement of the Endocannabinoid System in Motor Disorders
Current Medicinal Chemistry - Central Nervous System Agents Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Exploring Genetic Influences on Cognition: Emerging Strategies for Target Validation and Treatment Optimization
Current Drug Targets - CNS & Neurological Disorders Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy